Lightspring / Shutterstock.com
India’s system for protecting IP rights has been strongly criticised in the West and equally strongly defended in India itself. The truth, as WIPR discovered, is more complicated.
“India has some of the best chemists in the world and ought to have a huge innovative pharmaceutical industry, but there is a certain level of protectionism stopping that from happening,” says Jason Rutt, executive at Rouse & Co International LLP.
Despite such creative potential however, India has been criticised, particularly in the West, for cheating pharmaceutical companies and favouring their generic rivals. In its annual Special 301 Report this year, the US Trade Representative said some innovators, particularly in the pharma sector, face “serious challenges” in securing and enforcing their patents in India.
US drug giant Pfizer has gone further, writing to the Indian government earlier in the year urging it to “shift from using destructive IP policy as an access strategy”.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on email@example.com.
Pfizer; pharmaceuticals; patents; India; USTR;